Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lorrain, D. S.
  • Bain, G.
  • Correa, L. D.
  • Chapman, C.
  • Broadhead, A. R.
  • Santini, A. M.
  • Prodanovich, P.
  • Darlington, J. V.
  • Hutchinson, J. H.
  • King, C.
  • Lee, C.
  • Baccei, C.
  • Li, Yiwei
  • Arruda, J. M.
  • Evans, J. F.

publication date

  • December 2009

journal

  • Journal of Pharmacology and Experimental Therapeutics  Journal

subject areas

  • 5-Lipoxygenase-Activating Proteins
  • Acute Disease
  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal
  • Asthma
  • Carrier Proteins
  • Chronic Disease
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Extravasation of Diagnostic and Therapeutic Materials
  • Female
  • Humans
  • Indoles
  • Inflammation
  • Leukotriene B4
  • Male
  • Membrane Proteins
  • Mice
  • Mice, Inbred BALB C
  • Pneumonia
  • Propionates
  • Rats
  • Rats, Sprague-Dawley
  • Zymosan
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0022-3565

Digital Object Identifier (DOI)

  • 10.1124/jpet.109.158089

PubMed ID

  • 19749079
scroll to property group menus

Additional Document Info

start page

  • 1042

end page

  • 1050

volume

  • 331

issue

  • 3

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support